Two Sigma Advisers LP Reduces Position in Masimo Co. (NASDAQ:MASI)

Two Sigma Advisers LP decreased its position in Masimo Co. (NASDAQ:MASI) by 97.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,500 shares of the medical equipment provider’s stock after selling 214,100 shares during the period. Two Sigma Advisers LP’s holdings in Masimo were worth $744,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Jones Financial Companies Lllp purchased a new stake in shares of Masimo in the fourth quarter valued at approximately $27,000. Blue Trust Inc. boosted its holdings in shares of Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 71 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Masimo by 40.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider’s stock valued at $37,000 after purchasing an additional 64 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Masimo by 31.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 60 shares during the period. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of Masimo in the fourth quarter valued at approximately $46,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Insider Activity at Masimo

In related news, COO Bilal Muhsin sold 30,000 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the transaction, the chief operating officer now directly owns 24,172 shares of the company’s stock, valued at $4,048,568.28. This represents a 55.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the company’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the transaction, the director now directly owns 16,581 shares in the company, valued at approximately $2,754,601.53. The trade was a 11.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 42,053 shares of company stock valued at $6,998,565 in the last ninety days. Company insiders own 9.70% of the company’s stock.

Masimo Stock Performance

Shares of MASI stock opened at $165.03 on Tuesday. The business’s fifty day simple moving average is $157.10 and its 200-day simple moving average is $167.26. The company has a market cap of $8.95 billion, a PE ratio of 113.81 and a beta of 1.23. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. Masimo Co. has a 12-month low of $101.61 and a 12-month high of $194.88.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.24 by $0.12. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The firm had revenue of $372.00 million for the quarter, compared to the consensus estimate of $367.79 million. During the same period in the prior year, the firm earned $0.77 EPS. The firm’s revenue was down 24.5% on a year-over-year basis. Analysts expect that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on MASI. Raymond James reduced their price objective on shares of Masimo from $204.00 to $185.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. Wall Street Zen downgraded shares of Masimo from a “buy” rating to a “hold” rating in a research note on Friday. BTIG Research set a $193.00 price objective on shares of Masimo and gave the stock a “buy” rating in a research note on Wednesday, May 7th. Piper Sandler reissued an “overweight” rating and issued a $200.00 price objective (down previously from $215.00) on shares of Masimo in a research note on Wednesday, May 7th. Finally, Wells Fargo & Company reduced their price objective on shares of Masimo from $205.00 to $190.00 and set an “overweight” rating for the company in a research note on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $191.60.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.